Tracers / [212Pb]Pb-PSMA-617

[212Pb]Pb-PSMA-617

Also written as PSMA-617; Pluvicto; [Pb-212]Pb-PSMA-617
Radionuclide
Pb-212 t½ 638.4 min
Modality
Therapy
Production route
Stage
Syntheses indexed
2

What it is

Compound class
PSMA-617, a PSMA-targeted urea-based small-molecule radioligand
Target / mechanism
PSMA (prostate-specific membrane antigen) PMID 42159963
Clinical application
Treatment of advanced prostate cancer PMID 42159963
Theranostic pair
<a href="/tracers/in111-psma617/">in111-psma617</a>

Regulatory status

FDA
EMA (centralised)
Other approvals
Brand names

Clinical use

Typical injected activity
Uptake time

Reported in the literature. Not a dosing recommendation.

Published syntheses

ModuleCassettePurificationYield %RCP %Precursor / supplierSource
Manual synthesisSPE46.3 ± 1.7%>98%PSMA-617
Novartis
42159963
2026 EJNMMI Radiopharm Chem
In a 1.5 mL protein Eppendorf tube (LoBind®), approximately 37.0 MBq of 177LuCl3 in 0.25 M NaOAc buffer (pH 5.5, 100 µL) or 18.5 MBq of 212PbCl2 in 0.2 M NaOAc buffer (pH 5.5, 100 µL) was mixed with PSMA-617 (1.0 nmol, 1.0 µL). — Sep-Pak purification of the crude mixture after radiolabeling yielded [212Pb]Pb-PSMA-617 in 46.3 ± 1.7% (n = 4) yield
PSMA-61731919866
2020 J Labelled Comp Radiopharm
Both ligands were efficiently labelled with 212 Pb using a 224 Ra/212 Pb-solution generator in transient equilibrium with progeny.

Need this precursor?We can point you to suppliers for [212Pb]Pb-PSMA-617, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Diagnostic pair signal at discovery: YES - Ga-68, In-111. Compound class inferred from precursor name (not stated outright) -- PMID 42159963: 'PSMA-617'.